Evolocumab Shows No Significant Cost-effectiveness for Myocardial Infarction in China

被引：0
|
作者：
Liang, Zhe
Chen, Qi
Zhao, Quanming
机构：
来源：
CIRCULATION | 2020年 / 142卷
关键词：
D O I：
10.1161/circ.142.suppl_3.13636
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A13636
引用
收藏
页数：2
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF EVOLOCUMAB IN PATIENTS WITH PRIOR MYOCARDIAL INFARCTION IN CANADA
    Urbich, M.
    Jobin, M.
    Rogoza, R.
    VALUE IN HEALTH, 2020, 23 : S495 - S495
  • [2] Cost-Effectiveness of Evolocumab Therapy for Myocardial Infarction: The Chinese Healthcare Perspective
    Liang, Zhe
    Chen, Qi
    Yang, Fei
    Yan, Xianliang
    Zhang, Xuehui
    Chen, Xue
    Fang, Fang
    Zhao, Quanming
    CARDIOVASCULAR DRUGS AND THERAPY, 2021, 35 (04) : 775 - 785
  • [3] Cost-Effectiveness of Evolocumab Therapy for Myocardial Infarction: The Chinese Healthcare Perspective
    Zhe Liang
    Qi Chen
    Fei Yang
    Xianliang Yan
    Xuehui Zhang
    Xue Chen
    Fang Fang
    Quanming Zhao
    Cardiovascular Drugs and Therapy, 2021, 35 : 775 - 785
  • [4] COST-EFFECTIVENESS OF ALIROCUMAB FOR MYOCARDIAL INFARCTION IN CHINA
    Liang, Z.
    Chen, Q.
    Zhao, Q.
    ATHEROSCLEROSIS, 2021, 331 : E252 - E252
  • [5] COST-EFFECTIVENESS OF ALIROCUMAB FOR MYOCARDIAL INFARCTION IN CHINA
    Liang, Zhe
    Chen, Qi
    Zhao, Quanming
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 1565 - 1565
  • [6] Methodology and results of cost-effectiveness of LDL-C lowering with evolocumab in patients with acute myocardial infarction in China
    Yuansheng Wan
    Jinyu Liu
    Xiaolian Zhan
    Yu Zhang
    Ruxu You
    Cost Effectiveness and Resource Allocation, 21
  • [7] Methodology and results of cost-effectiveness of LDL-C lowering with evolocumab in patients with acute myocardial infarction in China
    Wan, Yuansheng
    Liu, Jinyu
    Zhan, Xiaolian
    Zhang, Yu
    You, Ruxu
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2023, 21 (01)
  • [8] Cost-effectiveness of Evolocumab
    Escobar, Carlos
    Barrios, Vivencio
    REVISTA ESPANOLA DE CARDIOLOGIA, 2018, 71 (12): : 1089 - 1089
  • [9] Cost, effectiveness and cost-effectiveness of therapies in acute myocardial infarction
    Greene, RJ
    Thornton, BA
    Arora, RR
    CIRCULATION, 1997, 96 (08) : 1009 - 1009
  • [10] Cost-effectiveness of Evolocumab. Response
    de Labry Lima, Antonio Olry
    Matas Hoces, Antonio
    Alegre del Rey, Emilio Jesus
    Gimeno Ballester, Vicente
    REVISTA ESPANOLA DE CARDIOLOGIA, 2018, 71 (12): : 1090 - 1090
12345